The value of sex hormone binding globulin (SHBG) in predicting treatment response in polycystic ovary syndrome (PCOS)

Clinical Laboratory

Volumn 57, Issue 1-2, 2011, Pages 95-98

  Wassell, Julie ^a   Michail, M ^b   Soliman, N ^c   Wardle, P G ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^c YEOVIL DISTRICT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; SEX HORMONE BINDING GLOBULIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CHEMICAL ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OBSTETRICS; OVARY POLYCYSTIC DISEASE; PREDICTIVE VALUE; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; POLYCYSTIC OVARY SYNDROME; SEX HORMONE-BINDING GLOBULIN; TREATMENT OUTCOME;

EID: 79953821830     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Dokras A Cardiovascular disease risk factors in polycystic ovary syndrome. Semin Reprod Med 2008; 26: 39-44.
2. Palomba S, Falbo A, Zullo F and Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009; 30: 1-50.
3. Sharma ST and Nestler JE. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers. Best Pract Res Clin Endocrinol Metab 2006; 20: 245-60. (Pubitemid 43842921)
4. Sahin Y, Unluhizarci K, Yilmazsoy A, Yikilmaz A, Aygen E, Kelestimur F. The effects of metformin on metabolic syndrome and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Clin Endocrinol 2007; 67: 904-8. (Pubitemid 350135135)
5. Agarwal N, Rice SP, Bolusani H et al. Metformin reduced arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo controlled crossover trial. J Clin Endocrinol Metab 2010; 95: 722-30.
6. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulinsensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligoamenhorrhoea and subfertility. Cochrane Database Syst Rev 2009; 7: CD003053.
7. Leeman L and Acharya U. The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence. J Obstet Gynaecol 2009; 29: 467-72.
8. Tan S, Hahn S, Benson S et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin. European Journal of Endocrinology 2007; 157: 669-76. (Pubitemid 350187385)
9. Legro RS, Castracane VD, Kaufmann RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstetrical and Gynaecological Survey 2004; 59: 141-154. (Pubitemid 38140845)
10. Mero AA, Huovinen H, Matintupo O et al. Moderate energy restriction with high protein diet results in healthier outcome in women. J Int Soc Sports Nutr 2010; 25: 4.
11. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone binding globulin in the human hepatoma (hep G2) cell line in insulin and prolactin. J Clin Endocrinol Metab 1988; 67: 460-4.
12. Perry JR, Weedon MN, Langenberg C et al. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type II diabetes. Hum Mol Genet 2010; 19: 535-44.
13. Ding EL, Sang Y, Manse JE et al. Sex-hormone binding globulin and risk of type II diabetes mellitus in women and men. N Engl J Med 2009; 361: 1152-63.
14. Pugeat M, Nader N, Hageveen K et al. Sex hormone binding globulin expression in the liver: drugs and the metabolic syndrome. Mol Cell Endocrinol 2010; 316: 53-9.
15. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormonebinding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endrocrinol Metab 2003; 88: 1528-33. (Pubitemid 36623365)
16. Ducluzeau PH, Cousin P, Malvoisin E et al. Glucose-to-insulin ratio rather than sex hormone binding globulin and adiponectin levels is the best predictor of insulin resistance in non-obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 2003; 3626-31. (Pubitemid 37034505)
17. Marcondes JA, Yamashita SA, Maciel GA, Baracat EC and Halpern A. Metformin in normal weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. Gynecological Endocrinology 2007; 23: 273-8. (Pubitemid 46897699)
18. Orio F, Manguso F, Di Biase S et al. Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. European Journal of Endocrinology 2007; 157: 69-73. (Pubitemid 47162568)